Related Experiment Video
Updated: May 11, 2025
Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
Treatment of non-ST-segment elevation myocardial infarction in the elderly: the SENIOR-RITA trial
Stefano Savonitto1, Giuseppe De Luca2,3, Stefano De Servi4
1Clinica San Martino, Malgrate, Italy.
Insights
For elderly patients with non-ST-segment elevation myocardial infarction, an invasive strategy showed no mortality benefit over a conservative approach. However, it reduced infarction risk and revascularization needs.
Area of Science:
- Cardiology
- Geriatric Medicine
- Clinical Trials
Background:
- Non-ST-segment elevation myocardial infarction (NSTEMI) is common in older adults.
- The optimal management strategy (invasive vs. conservative) for NSTEMI in the elderly remains debated.
- Previous studies lacked definitive evidence on mortality benefits of invasive approaches.
Purpose of the Study:
- To compare the efficacy of an invasive versus a conservative strategy in elderly patients (≥75 years) with NSTEMI.
- To evaluate the impact on mortality, cardiovascular death, and infarction.
- To assess the need for subsequent revascularization.
Main Methods:
- The SENIOR-RITA trial randomized 1518 elderly patients to either an invasive or conservative management strategy.
- Follow-up extended to over 4 years.
- Frail patients with cognitive impairment and comorbidities were included.
Main Results:
- No significant difference was observed between the invasive and conservative strategies regarding the primary endpoint (cardiovascular death and infarction) or overall mortality.
- The invasive strategy led to a significant reduction in the risk of infarction.
- A significant reduction in subsequent revascularization was noted in the invasive strategy group.
Conclusions:
- For elderly NSTEMI patients, an invasive strategy does not improve mortality compared to a conservative approach.
- The findings support considering an invasive strategy for reducing infarction risk and revascularization needs in this population.
- Future antithrombotic therapies should account for patient frailty and high bleeding risk.
Abstract:
Non-ST-segment elevation myocardial infarction is the prevalent form of infarction, especially in the elderly population. Compared with ST-segment elevation myocardial infarction, the culprit coronary artery lesion is not always traceable, and only a proportion of cases undergoing coronary angiography result in revascularization. At present, there is no evidence that a systematically invasive strategy has better outcomes, especially lower mortality, than a conservative approach. The SENIOR-RITA trial was the largest study in this regard, having randomized 1518 patients aged ≥75 years to invasive vs. conservative strategy with follow-up up to more than 4 years. Frail patients with cognitive impairment and comorbidities were not excluded. The results showed no differences between the two strategies in terms of primary endpoint (composite of cardiovascular death and infarction) or mortality, but a significant reduction in the risk of infarction and subsequent revascularization. These results confirm those of the previous meta-analysis of studies devoted to elderly patients and should be considered in terms of intervention strategy rather than revascularization efficacy. Subsequent antithrombotic therapies need to consider the frailty of these patients and their high haemorrhagic risk, with the increasing trend towards less aggressive and prolonged therapies than in the past.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Alzheimer's Disease: Treatment
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...